DNA tumoral circulante na detecção da doença residual molecular e na predição de recidiva tumoral: avanços recentes e perspectivas clínicas.
Introduction: liquid biopsy, through the analysis of circulating tumor DNA (ctDNA), has become established in precision oncology as a tool to detect molecular residual disease and predict recurrence in solid tumors. Objective: to review recent advances in the use of ctDNA during follow-up after curative-intent treatment, highlighting clinical applications, therapeutic implications and current limitations. Methods: narrative literature review with a structured search strategy in PubMed/MEDLINE, SciELO and Google Scholar, using DeCS and MeSH descriptors combined with Boolean operators, covering 2021 to 2026; after screening of titles, abstracts and full texts, nine studies made up the final sample. Results: ctDNA detection after curative treatment identifies high-risk patients before radiological progression, with the most consistent evidence in colorectal cancer and promising results in breast cancer, non-small cell lung cancer and melanoma. Tumor-informed and tumor-agnostic approaches support risk stratification and individualized therapeutic decisions, including escalation and de-escalation of adjuvant therapy. However, analytical and clinical challenges remain, such as false-positive results caused by clonal hematopoiesis, reduced sensitivity at certain anatomical sites, lack of standardized protocols and high cost. Conclusion: ctDNA is a promising biomarker for the early detection of molecular residual disease and recurrence prediction, supporting personalized cancer care; nevertheless, its broad clinical adoption depends on further prospective validation, methodological standardization and cost reduction.
Authors
- Marcos Martins Silva (ORCID: https://orcid.org/0000-0002-9893-1975)
- Rafael Ramos Teles (ORCID: https://orcid.org/0009-0009-4715-5791)
- Patrícia Maia (ORCID: https://orcid.org/0000-0002-5291-2066)
- Laysla Tamyres de Oliveira Borges (ORCID: https://orcid.org/0009-0007-8339-383X)
- Paulo Jorge Oliveira (ORCID: https://orcid.org/0000-0002-5201-9948)
- Natalia Maria Valeriano da Silva (ORCID: https://orcid.org/0009-0005-5189-9962)
- Victor Buarque Ribeiro de Siqueira (ORCID: https://orcid.org/0009-0009-5736-7261)
- Maria Clara Gomes Oliveira (ORCID: https://orcid.org/0009-0004-2389-4278)
- Mariana Gaspar Côrte Real (ORCID: https://orcid.org/0009-0004-1763-5579)
- João Eduardo Cordeiro Ferreira dos Santos (ORCID: https://orcid.org/0009-0009-2167-0955)
Publication Details
- Journal
- Revista fisio&terapia.
- Published
- 2026-11-16
- DOI
- https://doi.org/10.69849/jsx60n93
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00